Compare RUN & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUN | IMVT |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.3B |
| IPO Year | 2015 | N/A |
| Metric | RUN | IMVT |
|---|---|---|
| Price | $18.26 | $25.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 9 |
| Target Price | $21.00 | ★ $30.78 |
| AVG Volume (30 Days) | ★ 8.9M | 1.5M |
| Earning Date | 02-26-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,316,656,000.00 | N/A |
| Revenue This Year | $19.15 | N/A |
| Revenue Next Year | $6.26 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.79 | N/A |
| 52 Week Low | $5.38 | $12.72 |
| 52 Week High | $22.44 | $27.92 |
| Indicator | RUN | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 45.84 | 48.62 |
| Support Level | $18.78 | $23.90 |
| Resistance Level | $21.18 | $27.92 |
| Average True Range (ATR) | 1.57 | 1.34 |
| MACD | -0.08 | -0.05 |
| Stochastic Oscillator | 13.53 | 46.23 |
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.